Einzeltreffer — DigiBib

Background: Prostate cancer is the leading cause of cancer-related death and the second most commonly diagnosed cancer among men in Uganda and most countries in Sub-Saharan Africa (SSA). The TMPRSS2-ERG fusion gene is the most common genetic alteration seen among prostate cancer patients. There are several contradicting reports about the association of ERG protein with poor prognosis, high PSA, and Gleason score. This study determined the prevalence of ERG expression and the relationship with PSA, Gleason score, and Age of prostate cancer patients in Southwestern Uganda.

Methods: We reviewed 130 archived prostate biopsy (needle and TURP) specimens from patients of age ≥ 50 years who had a histological diagnosis of prostate cancer. We obtained their biodata, and preoperative PSA, from the archived records. We did Immunohistochemistry (IHC) to determine the prevalence of ERG expression.

Results: The mean patient age in our study was 74.64 ± 10.19 years. Pre-operative PSA levels had been done for 79.2% of the participants. Most cancers (58.46%) were of high grade (grade group 3-5). ERG expression prevalence was 75.4% and its expression was independent of age, re-operative PSA, and Gleason score.

Conclusion: There is a significantly higher prevalence of ERG expression in our study compared to what is reported in other African-based studies. The expression of the ERG is independent of age, Gleason score, and serum PSA levels. A high proportion of our prostate cancer has high-grade disease at the time of diagnosis.

Titel:	A cross-sectional study of ERG expression and the relationship with clinicopathological features of Prostate cancer in Southwestern Uganda.
Autor/in / Beteiligte Person:	Mitala, Y ; Ssenkumba, B ; Birungi, A ; Kiconco, R ; Mutakooha, MM ; Atwine, R
Link:	Zum Volltext
Zeitschrift:	Diagnostic pathology, Jg. 19 (2024-05-10), Heft 1, S. 67
Veröffentlichung:	[London] : BioMed Central, 2006-, 2024
Medientyp:	academicJournal
ISSN:	1746-1596 (electronic)
DOI:	10.1186/s13000-024-01494-1
Schlagwort:	Humans Male Uganda epidemiology Cross-Sectional Studies Aged Middle Aged Aged, 80 and over Prostate-Specific Antigen blood Immunohistochemistry Prostatic Neoplasms pathology Prostatic Neoplasms epidemiology Prostatic Neoplasms genetics Transcriptional Regulator ERG genetics Neoplasm Grading Biomarkers, Tumor analysis
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Diagn Pathol] 2024 May 10; Vol. 19 (1), pp. 67. <i>Date of Electronic Publication: </i>2024 May 10. MeSH Terms: Prostatic Neoplasms* / pathology ; Prostatic Neoplasms* / epidemiology ; Prostatic Neoplasms* / genetics ; Transcriptional Regulator ERG* / genetics ; Neoplasm Grading* ; Biomarkers, Tumor* / analysis ; Humans ; Male ; Uganda / epidemiology ; Cross-Sectional Studies ; Aged ; Middle Aged ; Aged, 80 and over ; Prostate-Specific Antigen / blood ; Immunohistochemistry References: Prostate. 2019 Jul;79(10):1191-1196. (PMID: 31090091) ; Prostate. 2011 Apr;71(5):489-97. (PMID: 20878952) ; Cancer Res. 2006 Sep 1;66(17):8337-41. (PMID: 16951139) ; J Glob Oncol. 2016 Feb 17;2(4):181-185. (PMID: 28717700) ; Mod Pathol. 2010 Nov;23(11):1492-8. (PMID: 20693979) ; BJU Int. 2013 May;111(5):834-5. (PMID: 23578235) ; Korean J Pathol. 2012 Oct;46(5):423-8. (PMID: 23136568) ; APMIS. 2009 Aug;117(8):575-82. (PMID: 19664128) ; Cancer Cell Int. 2018 Nov 12;18:177. (PMID: 30459527) ; Prostate. 2014 Jun;74(8):880-91. (PMID: 24723425) ; Science. 2005 Oct 28;310(5748):644-8. (PMID: 16254181) ; Res Rep Urol. 2019 May 22;11:149-155. (PMID: 31192172) ; Ecancermedicalscience. 2018 Jan 16;12:797. (PMID: 29434663) ; Prostate Int. 2014 Sep;2(3):133-9. (PMID: 25325025) ; Asian Pac J Cancer Prev. 2014;15(7):3099-103. (PMID: 24815454) ; Eur Urol. 2008 Sep;54(3):581-8. (PMID: 18423977) ; Clin Cancer Res. 2009 Jul 15;15(14):4706-11. (PMID: 19584163) ; West Afr J Med. 2020 Jul-Aug;37(3):248-252. (PMID: 32476118) ; Neoplasia. 2010 Jul;12(7):590-8. (PMID: 20651988) ; Mol Med Rep. 2017 Oct;16(4):5450-5458. (PMID: 28849022) ; J Clin Oncol. 2014 Jan 20;32(3):206-11. (PMID: 24297949) ; Virchows Arch. 2011 Oct;459(4):441-7. (PMID: 21773753) ; Nat Rev Cancer. 2008 Jul;8(7):497-511. (PMID: 18563191) ; Clin Cancer Res. 2008 Jun 1;14(11):3380-5. (PMID: 18519767) ; Anticancer Res. 2016 Sep;36(9):4787-93. (PMID: 27630329) ; Am J Epidemiol. 2017 Dec 15;186(12):1352-1361. (PMID: 28633309) Contributed Indexing: Keywords: ERG; Immunohistochemistry; Prostate cancer; Uganda Substance Nomenclature: 0 (Transcriptional Regulator ERG) ; 0 (ERG protein, human) ; 0 (Biomarkers, Tumor) ; EC 3.4.21.77 (Prostate-Specific Antigen) Entry Date(s): Date Created: 20240510 Date Completed: 20240511 Latest Revision: 20240513 Update Code: 20240513 PubMed Central ID: PMC11084131

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

A cross-sectional study of ERG expression and the relationship with clinicopathological features of Prostate cancer in Southwestern Uganda.